- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Stacey McCullough on the Pharmacist's Role in Patient Education
With more oncology patients receiving oral therapies, the pharmacist plays an important role in patient education and follow-up, said Stacey McCullough, PharmD, senior vice president of pharmacy at Tennessee Oncology.
Transcript
What is the pharmacist’s role in initial patient education and follow-up?
At Tennessee Oncology, our pharmacists are the primary point for all of the initial oral oncolytic therapy education. We utilize manufacturer kits and we try to schedule enough time with the patient so that we can go over all the specifics of the care plan for that specific drug with the patient. We want to ask open-ended questions and ensure that they get all of their questions answered and ensure that the way we are delivering information is being interpreted and understood and fully comprehended to set the patient up for their best possible outcome.
How does collaboration and teamwork benefit care transition for patients?
Collaboration is so important, especially in oncology today. With patients receiving oral therapies, the pharmacy may be their bridge correlation to how the nurse was that bridge for IV therapy. The pharmacy is now gonna play that role in monitoring the patient, doing the proactive phone calls as well as the refill calls. So, how we’re able to get that information back into the care teams, be it the provider or the nurse, to facilitate that one point of contact for the patient and ensure that they know they can have all their questions answered and having that continuum of care is very important.
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More
New Study Finds Risk Groups, Outpatient Care Barriers in Chronic Liver Disease
November 20th 2024Patients with chronic liver disease who were unable to establish care were 85% more likely to require recurrent hospitalizations. This group included a disproportionate number of women and individuals with physical limitations affecting their health.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM
November 19th 2024The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).
Read More
